RAD51-IN-1, a derivative of B02, is a potent inhibitor of RAD51. RAD51-IN-1 can be used for cancer research.

Product information

CAS Number: 2101739-18-6

Molecular Weight: 373.83

Formula: C22H16ClN3O

Chemical Name: 3-[(4-chlorophenyl)methyl]-2-[(E)-2-(pyridin-3-yl)ethenyl]-3,4-dihydroquinazolin-4-one

Smiles: O=C1C2C=CC=CC=2N=C(/C=C/C2C=NC=CC=2)N1CC1C=CC(Cl)=CC=1

InChiKey: AQNDWTVLZSMOQU-FMIVXFBMSA-N

InChi: InChI=1S/C22H16ClN3O/c23-18-10-7-17(8-11-18)15-26-21(12-9-16-4-3-13-24-14-16)25-20-6-2-1-5-19(20)22(26)27/h1-14H,15H2/b12-9+

Technical Data

Appearance: Solid Power

Purity: ≥98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis

Storage Condition: Dry, dark and -20 ^oC for 1 year or refer to the Certificate of Analysis.

Shelf Life: ≥12 months if stored properly.

Stock Solution Storage: 0 - 4 ^oC for 1 month or refer to the Certificate of Analysis.

Drug Formulation: To be determined

HS Tariff Code: 382200

How to use

In Vitro:

RAD51 is a vital component of the homologous recombination DNA repair pathway and is overexpressed in drug-resistant cancers, including aggressive triple-negative breast cancer (TNBC). RAD51-IN-1 (10 μM) decreases the ratio of RAD51 positive cells/cH2AX positive cells in MDA-MB-231 cell exposure to 6 Gy irradiation. RAD51-IN-1 (10 μM) significantly inhibits DNA damage induced RAD51 foci formation with 6 Gy irradiation.

Products are for research use only. Not for human use.